Key Insights

Highlights

Success Rate

93% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 27/100

Termination Rate

3.8%

1 terminated out of 26 trials

Success Rate

92.9%

+6.4% vs benchmark

Late-Stage Pipeline

23%

6 trials in Phase 3/4

Results Transparency

54%

7 of 13 completed with results

Key Signals

7 with results93% success

Data Visualizations

Phase Distribution

16Total
Not Applicable (2)
P 1 (3)
P 2 (5)
P 3 (6)

Trial Status

Completed13
Recruiting6
Unknown3
Active Not Recruiting2
Withdrawn1
Terminated1

Trial Success Rate

92.9%

Benchmark: 86.5%

Based on 13 completed trials

Clinical Trials (26)

Showing 20 of 20 trials
NCT03422614RecruitingPrimary

Pathophysiology of Inborn Immunodeficiencies

NCT03414528CompletedPrimary

Identification of New Inborn Errors of Immunity

NCT04197596Phase 1Recruiting

Treatment of Refractory BK Infections With Related Donor BK Specific Cytotoxic T-cells (CTLs)

NCT04232085Phase 2RecruitingPrimary

Regenerative Medicine to Restore Hematopoiesis and Immune Function in Immunodeficiencies and Inherited Bone Marrow Failures

NCT03266653Phase 2Recruiting

EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection

NCT03266627Phase 2Recruiting

Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection

NCT03266640Phase 2Recruiting

Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)

NCT04354129Active Not RecruitingPrimary

Observational Study of Subcutaneous Immunoglobulin (Cutaquig) in Patients With Primary and Secondary Immunodeficiency.

NCT03939533Phase 3CompletedPrimary

Study to Monitor Subcutaneous Human Immunoglobulin Administered at Modified Dosing Regimens in Patients With Primary Immunodeficiency Diseases

NCT02888535CompletedPrimary

Intensive Care Unit and Secondary and Primary Immune Deficiency

NCT03037359UnknownPrimary

A Study About Low Blood Pressure in Patients With Primary Immunodeficiency Disease Treated With Immune Globulin Products

NCT03069079Not ApplicableCompletedPrimary

Investigation of Dental Health in Children With Neutrophil Defects: A Clinical Study

NCT03301168Phase 1Active Not Recruiting

Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant

NCT04354818Unknown

Coronavirus (COVID-19) Outcomes Registries in Immunocompromised Individuals Australia (CORIA)

NCT01888484Phase 3CompletedPrimary

Study of Octanorm Subcutaneous IG in Patients With PID

NCT02327351Phase 2CompletedPrimary

TCR Alpha/Beta Depletion for HSCT From Haploidentical and Unrelated Donors in the Treatment of PID

NCT03492710Phase 3WithdrawnPrimary

Study of Immune Globulin Intravenous (Human) GC5101F in Subjects With Primary Humoral Immunodeficiency

NCT03988426Phase 3CompletedPrimary

Study to Evaluate the Efficacy, Tolerability and Safety of Octanorm in Patients With Primary Immunodeficiency Diseases

NCT03618147CompletedPrimary

Primary Immunodeficiency in Kuwait

NCT01883921TerminatedPrimary

Gamma Globulin Observations and Outcomes Database for Patients With Primary Immunodeficiency Disease (GOOD-SHEPARD-PI)

Scroll to load more

Research Network

Activity Timeline